# Integer Holdings Corp: Form 10-Q for the period ended Oct 2, 2020

- Company: [Integer Holdings Corp](/companies/itgr.md) (CIK 1114483)
- Form: 10-Q
- Filed: 2020-10-29
- Accepted by EDGAR: Oct 29, 2020, 16:38 ET
- Period: 2020-10-02
- Accession: 0001114483-20-000020
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1114483/000111448320000020/gb-20201002.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1114483/000111448320000020/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-10-02.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-07-04 to 2020-10-02 | $235.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2020-01-01 to 2020-10-02 | $804.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2020-07-04 to 2020-10-02 | $178.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2020-01-01 to 2020-10-02 | $592.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2020-07-04 to 2020-10-02 | $57.9m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2020-01-01 to 2020-10-02 | $212.5m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2020-07-04 to 2020-10-02 | $3.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2020-01-01 to 2020-10-02 | $74.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-07-04 to 2020-10-02 | $39.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2020-01-01 to 2020-10-02 | $93.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-07-04 to 2020-10-02 | $9.4m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2020-01-01 to 2020-10-02 | $29.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-07-04 to 2020-10-02 | $1.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2020-01-01 to 2020-10-02 | $6.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-07-04 to 2020-10-02 | $30.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2020-01-01 to 2020-10-02 | $61.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-07-04 to 2020-10-02 | $0.92 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2020-01-01 to 2020-10-02 | $1.87 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-07-04 to 2020-10-02 | $0.92 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2020-01-01 to 2020-10-02 | $1.88 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-07-04 to 2020-10-02 | 33,076,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2020-01-01 to 2020-10-02 | 33,107,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2020-01-01 to 2020-10-02 | $110.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2020-01-01 to 2020-10-02 | $35.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-10-02 | $99.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-10-02 | $498.7m | us-gaap:AssetsCurrent |
| Total assets | at 2020-10-02 | $2.45bn | us-gaap:Assets |
| Current liabilities | at 2020-10-02 | $153.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-10-02 | $1.22bn | us-gaap:Liabilities |
| Long-term debt | at 2020-10-02 | $801.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2020-10-02 | $37.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2020-10-02 | $1.23bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 56,504 characters.

*This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the year ended December 31, 2019. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.*

### Forward-Looking Statements

Some of the statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include statements relating to:

- the impact of the COVID-19 global pandemic;
- future sales, expenses, and profitability;
- future development and expected growth of our business and industry;
- our ability to execute our business model and our business strategy;
- having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and
- projected capital spending.

You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or variations or the negative of these terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following:

- the duration, scope and impact of the COVID-19 pandemic, including government, social, business and other actions taken in response to the pandemic and the effect of the pandemic on our associates, suppliers and customers as well as the global economy;
- our dependence upon a limited number of customers;
- pricing pressures that we face from customers;
- our ability to respond to changes in technology;
- the intense competition we face and our ability to successfully market our products;
- our ability to develop new products and expand into new geographic and product markets;
- our reliance on third party suppliers for raw materials, key products and subcomponents;
- the potential for harm to our reputation caused by quality problems related to our products;
- regulatory issues resulting from product complaints, recalls or regulatory audits;
- the potential of becoming subject to product liability claims;
- our ability to protect our intellectual property and proprietary rights;
- our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities;
- our ability to integrate acquisitions and operate acquired businesses in accordance with expectations;
- our dependence upon our senior management team and technical personnel;
- our ability to realize the benefits from cost savings and consolidation initiatives;
- interruptions in our manufacturing operations;
- our ability to comply with environmental regulations;
- our complex international tax profile;
- our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures;
- market, financial and other risks related to our international operations and sales;
- global economic factors, including currency exchange rates and interest rates;
- the fact that the healthcare industry is highly regulated and subject to various regulatory changes;
- the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry; and

\- 29 -

- other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in other periodic filings with the Securities and Exchange Commission.

Except as required by applicable law, the Company assumes no obligation to update forward-looking statements in this report whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

In this Form 10-Q, references to “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries, unless the context indicates otherwise.

### Our Business

Integer Holdings Corporation is one of the largest medical device outsource (“MDO”) manufacturers in the world serving the cardiac, neuromodulation, vascular, orthopedics, advanced surgical and portable medical markets. We also develop batteries for high-end niche applications in the non-medical energy, military, and environmental markets. Our vision is to enhance the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

We organize our business into two reportable segments, Medical and Non-Medical, and derive our revenues from four principal product lines. The Medical segment includes the Cardio & Vascular, Cardiac & Neuromodulation and Advanced Surgical, Orthopedics & Portable Medical product lines and the Non-Medical segment comprises the Electrochem product line. For more information on our segments, please refer to Note 14 “Segment Information” of the Notes to Consolidated Financial Statements contained in Item 1 of this report.

The third quarter and first nine months of 2020 ended on October 2, 2020 and consisted of 91 days and 276 days, respectively. The third quarter and first nine months of 2019 ended on September 27, 2019 and consisted of 91 days and 273 days, respectively.

### Impact of COVID-19

We have continued to actively monitor the global spread of the novel coronavirus, or COVID-19, and, although the magnitude of the COVID-19 pandemic remains unpredictable, we continue to take steps in response to the pandemic to mitigate the impact to us posed by its spread and related third party responses, including from government authorities, our associates, customers and suppliers. We continue to prioritize the safety of our associates while continuing to provide critical products that patients rely on every day. Additionally, we have implemented numerous cost reduction actions to reduce discretionary expenses for the balance of the year. The following is a summary of a variety of the actions we have taken and continue to take.

### Governmental Actions

Regulatory authorities worldwide have imposed various and fluctuating restrictions regarding the conduct of business and the movement of people. However, we have been able to continue our operations throughout the pandemic because of the essential nature of the products we develop and manufacture. In response to the pandemic, many governments have also recently enacted legislation designed to support businesses and workers impacted by COVID-19. While we will seek benefits under this legislation where available, we do not expect that such benefits will have a material impact on our operations and financial condition.

### Associates

The health and safety of our associates is a priority for us. We have implemented measures to safeguard our associates from COVID-19 infection and exposure, consistent with guidelines promulgated by the World Health Organization, the United States Center for Disease Control, and other applicable regional authorities. These measures consist of policies, procedures, protocols, and guidance related to, among other things, COVID-19 symptom awareness, effective hygiene practices, travel restrictions, visitor restrictions, social distancing, face covering expectations, temperature and health screening, work-from-home requirements, absenteeism policies, enhanced workplace cleaning, and large-scale decontamination.

To balance cost management during what we expect to be temporary sales declines in certain areas, we are utilizing reductions-in-force, furloughs and temporary shutdowns to more closely align labor with customer demand, and we will continue to assess the need for further actions in this area. In doing so, we are monitoring benefits available to our associates under various governmental programs, including assistance for associates unable to work for COVID-19 reasons. We have sought, and will continue to seek to understand whether these benefits apply to our associates, how the available benefits support the best interests of our associates, and how the available benefits may impact our business now and in the future as we return to more normalized operations.

\- 30 -

### Customers

Likewise, we remain in close contact with our customers to respond to increased critical needs such as ventilator and patient monitor components and to understand the impact of COVID-19 on their business. COVID-19 has introduced volatility and uncertainty to all of our customers, which has resulted in the need for us to react and respond. As expected, we did experience decreased sales in the second and third quarters of 2020, largely because of delays in medical procedures. Because of our position in the supply chain, any delayed or reduced customer demand that we continue to experience will likely lag any similar delay or reduction in sales by our customers to their customers. This impact could be mitigated or enhanced depending on the various inventory management approaches utilized by our customers. We have had, and will continue to have, close conversation with our customers to be in the best possible position to respond to their needs.

### Supply Chain

Our suppliers are also experiencing the impact of COVID-19 on their businesses. Our suppliers have had challenges in maintaining an adequate workforce, securing materials from their own suppliers, implementing workplace safety practices, and have instituted periodic closures as a result of COVID-19. We are taking steps to validate our suppliers’ ability to continue to deliver to us on time, which may also be affected by the impact of COVID-19 on their own financial condition.

### Internal Controls over Financial Reporting and Disclosure Controls

We have taken proactive measures to ensure we have maintained an appropriate internal control environment while certain of our workforce continue to work from home. Our control environment allows access to technology and online communications that has not required a change in controls. We believe our existing disclosure controls are appropriate to address the financial reporting implications as a result of the COVID-19 pandemic.

### Governance

We are conducting regular leadership calls with global and regional leaders to review the effectiveness of associate safety measures, monitor the spread of the virus in the geographies in which we operate, discuss the evolving availability of testing and therapeutic medicine, and assess the impact of the pandemic on our business. These meetings also serve to ensure that progress continues on actions we have identified to manage COVID-19 risks or opportunities on an enterprise-wide or on a regional basis. Moreover, through formal meetings and other communications, we are in regular contact with our Board of Directors and Committees of the Board of Directors on the COVID-19 pandemic risks. This regular contact provides opportunities to ensure our board members remain informed, and can perform their duties of risk oversight. This communication also allows management to gain the valuable business and governance perspectives of our board members. Most importantly, we have been communicating with all associates regularly regarding, among other things, the steps we are taking to safeguard their health and safety, the flexible work and pay arrangements we have instituted as result of the COVID-19 pandemic, and the progress we are making in managing the effects of the pandemic on our business.

### Discontinued Operations

On July 2, 2018, we completed the sale of the Advanced Surgical and Orthopedic product lines (the “AS&O Product Line”) to Viant. In connection with the sale, the parties executed a transition services agreement whereby we provided certain corporate services (including accounting, payroll, and information technology services) to Viant to facilitate an orderly transfer of business operations. Viant paid us for these services as specified in the transition services agreement, which were complete as of June 28, 2019. The results of operations of the AS&O Product Line were classified as discontinued operations. All results and information presented exclude discontinued operations unless otherwise noted. Refer to Note 16 “Discontinued Operations” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information.

### Recent Business Acquisitions

On February 19, 2020, we acquired certain assets and liabilities of InoMec Ltd. (“InoMec”), a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enables us to create a research and development center in Israel, closer to the customer base in the region.

In October 2019, we purchased certain assets and liabilities of US BioDesign, LLC (“USB”), a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The acquisition added a differentiated capability related to the development and manufacture of complex braided and formed biomedical structures to our broad portfolio, that we believe further positions us as a partner of choice for innovative medical technologies.

Refer to Note 2 “Business Acquisitions” of the Notes to Consolidated Financial Statements contained in Item 1 of this report for additional information about these acquisitions.

\- 31 -

### Patent Litigation

In April 2013, we commenced an action against a competitor alleging they had infringed on the our patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate our patented technology. Following four trials, the Company was awarded $27.8 million in damages. In July 2020, the United States Court of Appeals for the Federal Circuit affirmed, in all respects, the judgment in favor of the Company. We recognized a net gain of $28.2 million during the third quarter of 2020. Including damages and post-judgment interest, we expected to receive $28.9 million. On October 15, 2020, we received a partial payment of $28.3 million and received the balance of $0.6 million on October 26, 2020. The proceeds were used to pay down a portion of our Revolving Credit Facility.

The successful conclusion of this litigation reinforces our commitment to protect our intellectual property, supporting our vision to enhance patient lives by being our customers’ partner of choice for innovative medical technologies and services. Refer to Note 10 “Commitments and Contingencies” of the Notes to Consolidated Financial Statements contained in Item 1 of this report for additional information on this matter.

### Strategic Overview

We continue to take steps to better align our resources in order to invest to grow and protect, and preserve our portfolio of products. In addition to our portfolio strategy, we have launched the execution of six key operational strategic imperatives designed to drive excellence in everything we do:

- Sales Force Excellence: We are changing the organizational structure to match product line growth strategies and customer needs. This change is about getting more out of the capabilities we already have, and will increase individual accountability and clarity of ownership, while serving customers more effectively.
- Market Focused Innovation: We are ensuring we get the most return on our research and development investments. Integer is currently focusing on getting a clearer picture of how we spend our money and ensuring we are spending it in the right places so we can increase investments to drive future growth.
- Manufacturing Excellence: The goal is to deliver world-class operational performance in the areas of safety, quality, delivery and overall efficiency. We want to transition our manufacturing into a competitive advantage through a single, enterprise-wide manufacturing structure known as the Integer Production System. This system will provide standardized systems and processes by leveraging best practices and applying them across all of our global sites.
- Business Process Excellence: Integer is taking a systematic approach to driving excellence in everything we do by standardizing, optimizing and ultimately sustaining all of our processes.
- Leadership Capability: We have a robust plan to make leadership a competitive advantage for Integer, and since the success rate is higher with internal hires, we are focusing on finding and developing leaders from within the Company to build critical capabilities for future success.
- Performance Excellence: We are raising the bar on associate performance to maximize our impact. This includes aligning key roles with critical capabilities, positioning the best talent against the biggest work, and putting tools and processes in place to provide higher financial rewards for top performers, so our top performers can see increased results in pay for increased results in their performance.

We believe Integer is well-positioned within the medical technology and MDO manufacturing market and that there is a robust pipeline of opportunities to pursue. We have expanded our medical device capabilities and are excited about opportunities to partner with customers to drive innovation. We believe we have the scale and global presence, supported by world-class manufacturing and quality capabilities, to capture these opportunities. We are confident in our capabilities as one of the largest MDO manufacturers, with a long history of successfully integrating companies, driving down costs and growing revenues over the long-term. Ultimately, our strategic vision is to drive shareholder value by enhancing the lives of patients worldwide by being our customers’ partner of choice for innovative technologies and services.

\- 32 -

### Financial Overview of Continuing Operations

Income from continuing operations for the third quarter and first nine months of 2020 was $30.3 million, or $0.92 per diluted share, and $61.8 million, or $1.87 per diluted share, respectively, compared to income from continuing operations of $30.6 million, or $0.92 per diluted share, and $80.2 million, or $2.43 per diluted share, for the third quarter and first nine months of 2019, respectively. These variances are primarily the result of the following:

- Sales for the third quarter and first nine months of 2020 decreased $67.6 million and $128.0 million, respectively, when compared to the same periods in 2019, primarily due to the impact of the COVID-19 pandemic.
- Gross profit for the third quarter and first nine months of 2020 decreased $35.5 million and $66.5 million, respectively, primarily from a loss in volume leverage resulting from a decrease in sales due to the impact of the COVID-19 pandemic and price reductions given to our customers, partially offset by production efficiencies resulting from our Manufacturing Excellence strategic imperative.
- Operating expenses for the third quarter and first nine months of 2020 decreased $28.7 million and $24.5 million, respectively, compared to the same periods in 2019, primarily due to decreases in Selling, general and administrative expenses. Included in Selling, general and administrative expenses for the third quarter of 2020 is a gain of $28.2 million recognized in connection with previously mentioned patent litigation judgment.
- Interest expense for the third quarter and first nine months of 2020 decreased $3.0 million and $10.8 million, respectively, compared to the same periods in 2019, primarily due to lower interest rates.
- During the third quarter and first nine months of 2020, we recognized net gains on equity investments of $2.2 million and $4.0 million, respectively, compared to a net gain of $1.0 million and a net loss of $0.7 million for the third quarter and first nine months of 2019, respectively. Gains and losses on equity investments are generally unpredictable in nature.
- Other (income) loss, net for the third quarter and first nine months of 2020 was a loss of $1.2 million and income of $0.2 million, respectively, compared to income of $0.4 million and $0.9 million, respectively, for the third quarter and first nine months of 2019, primarily due to fluctuations in foreign currency gains and losses in the respective periods.
- We recorded provisions for income taxes of $1.1 million and $6.4 million for the third quarter and first nine months of 2020, respectively, compared with provisions for income taxes of $4.9 million and $15.3 million during the same periods in 2019. The changes in income tax were primarily due to relative changes in pre-tax income and the impact of discrete tax items.

\- 33 -

### Our Financial Results of Continuing Operations

The following tables present selected financial information from continuing operations derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share). All financial information presented is from continuing operations unless otherwise specified.

| Medical Sales: | Three Months Ended October 2, 2020 | September 27, 2019 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio & Vascular | 124,596 | $148,581 | $(23,985) | (16.1)% |
| Cardiac & Neuromodulation | 72,909 | 106,533 | (33,624) | (31.6)% |
| Advanced Surgical, Orthopedics & Portable Medical | 30,179 | 34,310 | (4,131) | (12.0)% |
| Total Medical Sales | 227,684 | 289,424 | (61,740) | (21.3)% |
| **Non-Medical** | 8,258 | 14,163 | (5,905) | (41.7)% |
| Sales | 235,942 | 303,587 | (67,645) | (22.3)% |
| Cost of sales | 178,009 | 210,201 | (32,192) | (15.3)% |
| Gross profit | 57,933 | 93,386 | (35,453) | (38.0)% |
| Gross profit as a % of sales | 24.6% | 30.8% |  |  |
| Selling, general and administrative expenses (“SG&A”) | 3,609 | 32,935 | (29,326) | (89.0)% |
| SG&A as a % of sales | 1.5% | 10.8% |  |  |
| Research, development and engineering costs (“RD&E”) | 11,892 | 11,729 | 163 | 1.4% |
| RD&E as a % of sales | 5.0% | 3.9% |  |  |
| Other operating expenses | 2,674 | 2,241 | 433 | 19.3% |
| Operating expenses | 18,175 | 46,905 | (28,730) | (61.3)% |
| Operating income | 39,758 | 46,481 | (6,723) | (14.5)% |
| Operating margin | 16.9% | 15.3% |  |  |
| Interest expense | 9,368 | 12,337 | (2,969) | (24.1)% |
| Gain on equity investments, net | (2,234) | (986) | (1,248) | NM |
| Other (income) loss, net | 1,224 | (369) | 1,593 | NM |
| Income from continuing operations before taxes | 31,400 | 35,499 | (4,099) | (11.5)% |
| Provision for income taxes | 1,058 | 4,913 | (3,855) | (78.5)% |
| Effective tax rate | 3.4% | 13.8% |  |  |
| Income from continuing operations | $30,342 | $30,586 | $(244) | (0.8)% |
| Income from continuing operations as a % of sales | 12.9% | 10.1% |  |  |
| Diluted earnings per share from continuing operations | $0.92 | $0.92 | $— | —% |

NM Calculated amount not meaningful

\- 34 -

### MANAGEMENT'S DISCUSSION AND ANALYSIS

| Medical Sales: | Nine Months Ended October 2, 2020 | September 27, 2019 | Change $% |  |
| --- | ---: | ---: | ---: | ---: |
| Cardio & Vascular | $432,885 | $451,552 | $(18,667) | (4.1)% |
| Cardiac & Neuromodulation | 252,404 | 337,932 | (85,528) | (25.3)% |
| Advanced Surgical, Orthopedics & Portable Medical | 92,041 | 98,544 | (6,503) | (6.6)% |
| Total Medical Sales | 777,330 | 888,028 | (110,698) | (12.5)% |
| **Non-Medical** | 27,153 | 44,429 | (17,276) | (38.9)% |
| Total Sales | 804,483 | 932,457 | (127,974) | (13.7)% |
| Cost of sales | 591,985 | 653,477 | (61,492) | (9.4)% |
| Gross profit | 212,498 | 278,980 | (66,482) | (23.8)% |
| Gross profit as a % of sales | 26.4% | 29.9% |  |  |
| SG&A | 73,969 | 101,034 | (27,065) | (26.8)% |
| SG&A as a % of sales | 9.2% | 10.8% |  |  |
| RD&E | 37,879 | 34,720 | 3,159 | 9.1% |
| RD&E, Net as a % of sales | 4.7% | 3.7% |  |  |
| Other operating expenses | 7,631 | 8,239 | (608) | (7.4)% |
| Operating expenses | 119,479 | 143,993 | (24,514) | (17.0)% |
| Operating income | 93,019 | 134,987 | (41,968) | (31.1)% |
| Operating margin | 11.6% | 14.5% |  |  |
| Interest expense | 29,002 | 39,779 | (10,777) | (27.1)% |
| (Gain) loss on equity investments, net | (3,954) | 666 | (4,620) | NM |
| Other income, net | (233) | (921) | 688 | (74.7)% |
| Income from continuing operations before taxes | 68,204 | 95,463 | (27,259) | (28.6)% |
| Provision for income taxes | 6,373 | 15,289 | (8,916) | (58.3)% |
| Effective tax rate | 9.3% | 16.0% |  |  |
| Income from continuing operations | $61,831 | $80,174 | $(18,343) | (22.9)% |
| Income from continuing operations as a % of sales | 7.7% | 8.6% |  |  |
| Diluted earnings per share from continuing operations | $1.87 | $2.43 | $(0.56) | (23.0)% |

NM Calculated amount not meaningful

\- 35 -

### MANAGEMENT'S DISCUSSION AND ANALYSIS

### Product Line Sales from Continuing Operations

For the third quarter and first nine months of 2020, Cardio & Vascular sales decreased $24.0 million, or 16%, and decreased $18.7 million or 4%, respectively, versus the comparable 2019 periods. Cardio & Vascular sales for the third quarter and first nine months of 2020 were negatively impacted by the COVID-19 pandemic and a blend of our customers’ responses across nearly all Cardio & Vascular markets. During the third quarter and first nine months of 2020, price reductions lowered Cardio & Vascular sales by $1.9 million and $5.7 million, respectively, in comparison to the 2019 periods. Foreign currency exchange rate fluctuations increased Cardio & Vascular sales for the third quarter and first nine months of 2020 by $0.6 million and $0.1 million, respectively, in comparison to the 2019 periods primarily due to U.S. dollar fluctuations relative to the Euro.

For the third quarter and first nine months of 2020, Cardiac & Neuromodulation sales decreased $33.6 million, or 32%, and $85.5 million or 25%, respectively, versus the comparable 2019 periods. Cardiac & Neuromodulation sales for the third quarter and first nine months of 2020 declined commensurate with the market impact and a blend of our customers’ responses. Additionally, the Nuvectra bankruptcy created a headwind of $3.1 million and $15.6 million for the third quarter and first nine months of 2020, respectively. During the third quarter and first nine months of 2020, price reductions lowered Cardiac & Neuromodulation sales by $2.4 million and $7.1 million, respectively, in comparison to the 2019 periods. Foreign currency exchange rate fluctuations did not have a material impact on Cardiac & Neuromodulation sales during the third quarter and first nine months of 2020 in comparison to the 2019 periods.

In addition to Portable Medical sales, Advanced Surgical, Orthopedic & Portable Medical includes sales to the acquirer of our AS&O Product Line, Viant, under long-term supply agreements entered into as of the closing of the divestiture for the sale of products by the Company to Viant. For the third quarter and first nine months of 2020, Advanced Surgical, Orthopedic & Portable Medical sales decreased $4.1 million, or 12%, and $6.5 million, or 7%, respectively, versus the comparable 2019 periods, driven by the impact of COVID-19 and a blend of our customers’ responses. During the third quarter and first nine months of 2020, price reductions lowered Advanced Surgical, Orthopedic & Portable Medical sales by $0.4 million and $1.4 million, respectively, in comparison to the 2019 periods. Foreign currency exchange rate fluctuations did not have a material impact on Advanced Surgical, Orthopedic & Portable Medical sales.

For the third quarter and first nine months of 2020, Non-Medical sales decreased $5.9 million, or 42%, and $17.3 million or 39%, respectively, versus the comparable 2019 periods, driven by a severe decline in the energy market and demand fall-out from the COVID-19 pandemic. Price reductions and foreign currency exchange rate fluctuations did not have a material impact on Non-Medical sales during the third quarter and first nine months of 2020 in comparison to the 2019 periods.

### Gross Profit

Changes to gross profit as a percentage of sales (“Gross Margin”) from the prior year were due to the following:

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Price(a) | (2.0)% | (1.8)% |
| Mix(b) | (0.7) | (0.7) |
| Volume Leverage(c) | (3.4) | (0.8) |
| Nuvectra Bankruptcy(d) | (0.1) | (0.2) |
| Total percentage point change to gross profit as a percentage of sales | (6.2)% | (3.5)% |

(a) Our Gross Margin for the third quarter and first nine months of 2020 was negatively impacted by price reductions given to our larger OEM customers in return for long-term volume commitments.

(b) Amounts represent the impact to our Gross Margin attributable to changes in the mix of product sales during the periods.

(c) Our gross margin for the third quarter and first nine months of 2020 was negatively impacted by lower sales from the COVID-19 pandemic. Given our indirect labor and overhead costs are less variable, and in most cases fixed, the reduction in sales negatively impacted gross margin. However, we continue to execute on our Manufacturing Excellence strategic imperative and maintain our facility infrastructure as we expect the sales decline to be temporary.

(d) Amount represents the impact to our Gross Margin for the third quarter and first nine months of 2020 of $0.3 million and $1.1 million, respectively, of pre-tax charges attributable to the Nuvectra Bankruptcy.

\- 36 -

### SG&A Expenses

Changes to SG&A expenses from the prior year were due to the following (in thousands):

|  | Change From Prior Year Three Months | Nine Months |
| --- | ---: | ---: |
| Transition services agreement(a) | $— | $2,733 |
| Patent litigation gain(b) | (28,167) | (28,167) |
| All other SG&A(c) | (1,159) | (1,631) |
| Net decrease in SG&A Expenses | $(29,326) | $(27,065) |

(a) Represents the amount included in SG&A Expenses which was charged to Viant for transition services during the first six months of 2019. We executed a transition services agreement in conjunction with the sale of the AS&O Product Line, whereby we agreed to provide certain corporate services (including accounting, payroll, and information technology services) to Viant to facilitate an orderly transfer of business operations. This provision of services under the agreement was completed during the second quarter of 2019.

(b) We recognized a net gain of $28.2 million during the third quarter of 2020 related to a patent litigation judgment. Refer to Note 10 “Commitments and Contingencies” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information on this matter.

(c) The net decreases in all other SG&A for the third quarter and first nine months of 2020 compared to the same periods of 2019 are primarily attributable to lower compensation and benefits cost, travel related expenses and depreciation expense, partially offset by an increase in amortization.

### RD&E

RD&E costs for the third quarter and first nine months of 2020 were $11.9 million and $37.9 million, respectively, compared to $11.7 million and $34.7 million for the third quarter and first nine months of 2019. The increase in RD&E costs for the third quarter and first nine months of 2020 compared to the same prior year periods is primarily attributable to increased compensation and benefits costs, consistent with our strategy to invest in capabilities for growth. RD&E expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations.

\- 37 -

### Other Operating Expenses

Refer to Note 8 “Other Operating Expenses” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further information related to these initiatives. Other Operating Expenses (“OOE”) consist of the following (in thousands):

|  | Three Months Ended October 2, 2020 | September 27, 2019 | Nine Months Ended October 2, 2020 | September 27, 2019 |
| --- | ---: | ---: | ---: | ---: |
| Strategic reorganization and alignment(a) | $— | $962 | $686 | $4,352 |
| Manufacturing alignment to support growth(b) | 36 | 515 | 224 | 1,661 |
| 2020 restructuring plan(c) | 858 | — | 2,275 | — |
| Acquisition and integration expenses(d) | 107 | — | 510 | — |
| Other general expenses(e) | 1,673 | 764 | 3,936 | 2,226 |
| Total other operating expenses | $2,674 | $2,241 | $7,631 | $8,239 |

(a) As a result of the strategic review of our customers, competitors and markets, we began taking steps in 2017 to better align our resources in order to enhance the profitability of our portfolio of products. These initiatives include improving our business processes and redirecting investments away from projects where the market does not justify the investment, as well as aligning resources with market conditions and our future strategic direction. Expenses for the third quarter and first nine months of 2020 and 2019 primarily consist of severance costs.

(b) In 2017, we initiated several initiatives designed to reduce costs, improve operating efficiencies and increase manufacturing capacity to accommodate growth. The plan involves the relocation of certain manufacturing operations and expansion of certain of our facilities.

(c) Our 2020 restructuring plan mainly consists of costs associated with executing our imperatives for sales force excellence, manufacturing excellence and business process excellence. These projects focus on changing our organizational structure to match product line growth strategies and customer needs, transitioning our manufacturing process into a competitive advantage and standardizing and optimizing our business processes.

(d) Amounts include expenses related to the purchase of certain assets and liabilities from USB and InoMec, net of a $0.5 million adjustment to the fair value of acquisition-related contingent consideration liabilities.

(e) Amounts include expenses related to other initiatives not described above, which relate primarily to actions to align labor with customer demand as a result of COVID-19 and the decline of the energy market, integration and operational initiatives to reduce future costs and improve operational efficiencies. The 2020 and 2019 amounts primarily include severance, information technology systems conversion expenses and expenses related to the restructuring of certain legal entities of the Company.

We continually evaluate our operating structure in order to maximize efficiencies and drive margin expansion.

### Interest Expense, Net

Interest expense consists primarily of cash interest and debt related charges, such as amortization of debt issuance costs and original issue discount. For the third quarter and first nine months of 2020, interest expense decreased $3.0 million and $10.8 million, respectively versus the comparable 2019 periods, primarily from a decrease in cash interest due to lower interest rates. The weighted average interest rates on outstanding borrowings for the three and nine months ended October 2, 2020 were 3.60% and 3.83%, respectively, compared to 4.96% and 5.08% for the comparable periods in 2019. The weighted average interest rates paid in 2020 reflect decreases in LIBOR subsequent to the first quarter of 2019 and reductions to the applicable interest rate margin of our Term Loan A facility. In November 2019, we reduced the applicable interest rate margins by amending our Senior Secured Credit Facilities.

Debt related charges decreased $0.5 million and $2.1 million, respectively, during third quarter and first nine months of 2020 when compared to the same periods in 2019, primarily attributable to lower accelerated write-offs (losses from extinguishment of debt) of deferred fees and original issue discount related to prepayments of portions of our Term Loan B facility. We had no losses from extinguishment of debt during the first nine months of 2020 compared to $0.3 million and $1.3 million, respectively, in the third quarter and first nine months of 2019. See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.

\- 38 -

As of October 2, 2020, approximately 76% of our principal amount of debt outstanding was subject to variable rates, in comparison to approximately 20% as of December 31, 2019. We enter into interest rate swap agreements in order to reduce our exposure to fluctuations in the LIBOR rate. See Note 13 “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our interest rate swap agreements.

### (Gain) Loss on Equity Investments, Net

During the third quarter and first nine months of 2020, we recognized net gains on our equity investments of $2.2 million and $4.0 million, respectively, compared to a net gain of $1.0 million and a net loss of $0.7 million during the third quarter and first nine months of 2019, respectively. Gains and losses on equity investments are generally unpredictable in nature. The amounts for both 2020 and 2019 relate to our share of equity method investee gains/losses including unrealized appreciation of the underlying interests of the investee. As of October 2, 2020 and December 31, 2019, the carrying value of our equity investments were $25.8 million and $22.3 million, respectively. See Note 13 “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further details regarding these investments.

### Other (Income) Loss, Net

Other (Income) Loss, Net for the third quarter and first nine months of 2020 was a loss of $1.2 million and income of $0.2 million, respectively, compared to income of $0.4 million and $0.9 million for the third quarter and first nine months of 2019, respectively. Other (Income) Loss, Net primarily comprises gains/losses from the impact of exchange rates on transactions denominated in foreign currencies. Our foreign currency transaction gains/losses are based primarily on fluctuations of the U.S. dollar relative to the Euro, Mexican peso, Uruguayan pesos, Malaysian ringgits, or Israeli shekel.

The impact of exchange rates on transactions denominated in foreign currencies included in Other (Income) Loss, Net for the third quarter and first nine months of 2020 were losses of $1.2 million and gains of $0.3 million, respectively, compared to gains of $0.3 million and $0.4 million for the third quarter and first nine months of 2019, respectively. We continually monitor our foreign currency exposures and seek to take steps to mitigate these risks. However, fluctuations in exchange rates could have a significant impact, positive or negative, on our financial results in the future.

### Provision for Income Taxes

We recognized income tax expense of $1.1 million for the third quarter of 2020 on $31.4 million of income from continuing operations before taxes (effective tax rate of 3.4%), compared to income tax expense of $4.9 million on $35.5 million of income from continuing operations before taxes (effective tax rate of 13.8%) for the same period of 2019. The income tax expense for the first nine months of 2020 was $6.4 million on income from continuing operations before taxes of $68.2 million (effective tax rate of 9.3%), compared to $15.3 million on income from continuing operations before taxes of $95.5 million (effective tax rate of 16.0%) for the same period of 2019.

There is a potential for volatility in our effective tax rate due to several factors including changes in the mix of pre-tax income from continuing operations and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, and settlements with taxing authorities and foreign currency fluctuations. We currently have various tax planning initiatives in place and continuously evaluate planning strategies aimed at reducing our effective tax rate over the long term. This includes strategies to realize deferred tax assets that would otherwise expire unutilized.

Our effective tax rate for 2020 differs from the U.S. federal statutory tax rate of 21% due principally to the net impact of the Company’s earnings outside the U.S., which are generally taxed at rates that differ from the U.S federal rate, the Global Intangible Low-Taxed Income (“GILTI”) tax, the availability of tax credits, and discrete tax benefits. The discrete tax benefits for 2020 are predominately related to excess tax benefits recognized upon vesting of RSUs or exercise of stock options, favorable return to provision adjustments related to the 2019 tax year, the net impact of a tax restructuring of the Company’s Malaysian legal entity, and the impact of Final Treasury Regulations issued in July 2020 for GILTI, and Foreign Derived Intangible Income.

\- 39 -

Our earnings outside the U.S. are generally taxed at blended rates that are marginally lower than the U.S. federal rate. The GILTI provisions require us to include foreign subsidiary earnings in excess of a deemed return on the foreign subsidiary’s tangible assets in our U.S. income tax return. The foreign jurisdictions in which we operate and where our foreign earnings are primarily derived, include Switzerland, Mexico, Uruguay, Malaysia and Ireland. While we are not currently aware of any material trends in these jurisdictions that are likely to impact our current or future tax expense, our future effective tax rates could be adversely affected by earnings being lower than anticipated in countries where we have lower effective tax rates and higher than anticipated in countries where we have higher effective tax rates, or by changes in tax laws or regulations. We regularly assess any significant exposure associated with increases in tax rates in international jurisdictions and adjustments are made as events occur that warrant adjustment to our tax provisions.

### Liquidity and Capital Resources

*(dollars in thousands)*

|  | October 2, 2020 | December 31, 2019 |
| --- | ---: | ---: |
| Cash and cash equivalents | $99,943 | $13,535 |
| Working capital | $345,193 | $236,317 |
| Current ratio | 3.25 | 2.32 |

Cash and cash equivalents at October 2, 2020 increased by $86.4 million from December 31, 2019, primarily as a result of cash generated from operating activities, inclusive of proceeds from the sale of accounts receivable under a supplier financing program, and net borrowings on our Senior Secured Credit Facility, partially offset by purchases of property, plant and equipment. As of October 2, 2020, we had $15.0 million of cash and cash equivalents held in time-deposits with original maturities that were less than 90 days. The increase in cash and cash equivalents is consistent with our actions to increase liquidity given the uncertainty surrounding the COVID-19 pandemic.

During the first nine months of 2020, we began utilizing supplier financing arrangements with financial institution to sell certain accounts receivable on a non-recourse basis. These transactions are treated as a sale of, and are accounted for as a reduction to, accounts receivable. The agreement transfers control and risk related to the receivables to the respective financial institution. We have no continuing involvement in the transferred receivables subsequent to the sale. Under these agreements, we accelerated the timing of $47.1 million of accounts receivable cash collections during the first nine months of 2020.

Working capital increased by $108.9 million from December 31, 2019, primarily due to an increase in cash and cash equivalents and prepaid expenses and other current assets supplemented by a decrease in current liabilities primarily from the payment of accrued incentive compensation and lower inventory purchases. Cash and cash equivalents increased primarily from cash generated by operating activities while prepaid expenses and other current assets increased primarily from the recognition of an asset associated with the aforementioned patent litigation judgment in the third quarter of 2020. Our increase in net working capital was partially offset by a decrease in accounts receivable resulting from lower sales volume.

At October 2, 2020, $12.2 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income or current period earnings. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.

### Summary of Cash Flow

The following cash flow summary information includes cash flows related to discontinued operations (in thousands):

*(in thousands)*

| Cash provided by (used in): | Nine Months Ended October 2, 2020 | September 27, 2019 |
| --- | ---: | ---: |
| Operating activities | $110,239 | $111,977 |
| Investing activities | (44,932) | (20,382) |
| Financing activities | 21,698 | (102,432) |
| Effect of foreign currency exchange rates on cash and cash equivalents | (597) | (13) |
| Net change in cash and cash equivalents | $86,408 | $(10,850) |

\- 40 -

***Operating Activities –*** During the first nine months of 2020, we generated cash from operations of $110.2 million, compared to $112.0 million for the first nine months of 2019. The decrease of $1.8 million was due to a decrease of $21.5 million in cash net income (net income plus adjustments to reconcile net income to net cash provided by operating activities), offset by an increase of $19.7 million in cash flow provided by working capital. The decrease in cash net income is primarily from lower gross profit from sales and gross margin declines partially offset by lower SG&A expenses, interest expense, and income tax expense. The increase in cash from working capital is the result of changes in certain assets and liabilities affecting cash flows, primarily an increase in cash flows from accounts receivable of $72.1 million, which decreased in the current year from lower sales and supplier financing, partially offset by a decrease in cash flows from prepaid expenses and other current assets and accounts payable of $31.0 million and $22.9 million, respectively.

***Investing Activities –*** The $24.6 million increase in net cash used in investing activities was primarily attributable to increased purchases of property, plant, and equipment of $10.5 million, intangible assets of $4.6 million, and cash paid of $5.2 million for the acquisition of certain assets and liabilities from InoMec Ltd. in the first quarter of 2020.

***Financing Activities –*** Net cash provided by financing activities for first nine months of 2020, was $21.7 million compared to $102.4 million used in financing activities for the first nine months of 2019. Financing activities during the first nine months of 2020 primarily included net borrowings of $21.9 million, compared to net payments of $102.1 million for the comparable 2019 period. During the second quarter of 2020, we borrowed an additional $160 million of our Revolving Credit Facility to protect against a prolonged pandemic coupled with financial market illiquidity. As of October 2, 2020, we have paid down $135 million of that additional borrowing. During the fourth quarter of 2020 we utilized the proceeds received in conjunction with the patent litigation judgment to repay in full the additional borrowing.

***Capital Structure –*** As of October 2, 2020, our capital structure consists of $839 million of debt, net of deferred debt issuance costs and unamortized discounts, outstanding under our Senior Secured Credit Facilities and 33 million shares of common stock outstanding. We continue to have access to $143.3 million of borrowing capacity under our Revolving Credit Facility, available for normal course of business and letters of credit. We are also authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. As of October 2, 2020, our contractual debt service obligations for the remainder of 2020, consisting of principal and interest on our outstanding debt, are estimated to be approximately $17 million. Actual principal and interest payments may be higher if, for instance, the applicable interest rates on our Senior Secured Credit Facilities increase, we borrow additional amounts on our Revolving Credit Facility, or we pay principal amounts in excess of the required minimums reflected in the contractual debt service obligations above.

Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and borrowings under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. We continually evaluate and consider various financing alternatives to enhance or supplement our existing financial resources, including our Senior Secured Credit Facilities. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all. In addition, the recent COVID-19 pandemic, which has caused disruption in the capital markets, could make any such financing more difficult and/or expensive.

***Credit Facilities*** - As of October 2, 2020, we had Senior Secured Credit Facilities that consist of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”) with outstanding borrowings of $50 million, (ii) a term loan A facility (the “TLA Facility”) with outstanding principal balance of $239 million, and (iii) a term loan B facility (the “TLB Facility”) with outstanding principal balance of $558 million. The Senior Secured Credit Facilities will mature on October 27, 2022. The Senior Secured Credit Facilities include a mandatory prepayment provision customary for credit facilities of its nature.

The Revolving Credit Facility and TLA Facility contain covenants requiring (A) a maximum total net leverage ratio of 4.75:1.0, subject to a step down to 4.50 to 1.00 for the third fiscal quarter of 2021, and reverting to and remaining at 4.00 to 1.00 beginning with the fourth quarter of 2021 through maturity, and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of 3.0:1.0. Additionally, the Net Leverage Ratio can be increased by 0.50 for up to four consecutive quarters commencing in any fiscal quarter in which we consummate an Eligible Adjustment Acquisition (as defined in the Amendment) with a $40 million or greater purchase price. The TLB Facility does not contain any financial maintenance covenants. As of October 2, 2020, our total net leverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 3.3 to 1.0. For the twelve month period ended October 2, 2020, our ratio of adjusted EBITDA to interest expense, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 6.8 to 1.0.

\- 41 -

Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us. As of October 2, 2020, we were in full compliance with the financial covenants described above. As of October 2, 2020, our adjusted EBITDA would need to decline by approximately $74 million, or approximately 30%, in order for us to not be in compliance with our financial covenants. The Revolving Credit Facility is supported by a consortium of twelve lenders with no lender controlling more than 27% of the facility.

See Note 6 “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further information on the Company’s outstanding debt.

### Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements within the meaning of Item 303(a)(4) of Regulation S-K.

### Impact of Recently Issued Accounting Standards

In the normal course of business, we evaluate all new accounting pronouncements issued by the Financial Accounting Standards Board, Securities and Exchange Commission, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 1 “Basis of Presentation” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.

### Contractual Obligations

There have been no significant changes to our contractual obligations during the quarter ended October 2, 2020 as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2019.

### Critical Accounting Policies and Estimates

The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.

There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2019.

\- 42 -

## Market risk

As filed, 607 characters.

Refer to information appearing under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q. Furthermore, a discussion of market risk exposures is included in Part II, Item 7A, Quantitative and Qualitative Disclosure about Market Risk, of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

Other than the uncertainties resulting from the global pandemic, there have been no material changes in reported market risk since the inclusion of this discussion in the Company’s Annual Report on Form 10-K referenced above.

## Controls and procedures

As filed, 1,416 characters.

a. Evaluation of Disclosure Controls and Procedures

Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of October 2, 2020. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of October 2, 2020, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.

b. Changes in Internal Control Over Financial Reporting

During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

\- 43 -

## Risk factors

As filed, 167 characters.

Information concerning our risk factors is contained in Item 1A of our Form 10-Q for the quarter ended April 3, 2020, and is incorporated by reference herein.

\- 44 -

Filed Oct 29, 2020.
Source: SEC EDGAR, the filing index for accession 0001114483-20-000020. Last ingested by Listed: Nov 11, 2026, 00:08 ET. No prices; not investment advice.
